Canada \u00b7 Ontario coverage
Is Mounjaro covered by OHIP? Where Ontario stands.
The short answer: not yet. OHIP doesn't pay for pharmacy prescriptions, and Mounjaro isn't on the Ontario Drug Benefit formulary. That could change for type 2 diabetes: Canada's Drug Agency issued a positive, conditional recommendation in 2026. Here is where things stand and how to check for yourself.
Last reviewed October 15, 2026against Health Canada's Drug Product Database and the Ontario Drug Benefit Formulary.
Ontario status on October 15, 2026
- Searching the ODB formulary for tirzepatide, Mounjaro or Zepbound returned no products.
- That means no coverage through ODB, OHIP+, Trillium, ODSP or Ontario Works for now, outside any case-by-case Exceptional Access review.
- For type 2 diabetes, Ontario does cover Ozempic and generic semaglutide injections as Limited Use benefits (see Ozempic coverage in Ontario).
What Canada's Drug Agency recommended
| Product | Use reviewed | Recommendation (2026) |
|---|---|---|
| Mounjaro | Type 2 diabetes, with metformin (alone or with a sulfonylurea or SGLT2 inhibitor) | Reimburse using existing GLP-1 criteria, only with a price reduction; not with other GLP-1s |
| Zepbound | Chronic weight management | Reimburse only for adults with BMI 27+ and prediabetes, with a price reduction; continue only with at least 5% weight loss after year one |
Sources: CDA-AMC recommendations for Mounjaro and Zepbound, published August 2026. A recommendation is advice to public plans, not coverage. Provinces decide after price negotiations.
If you're prescribed Mounjaro in Ontario now
- Check your workplace or private plan. Some cover Mounjaro for type 2 diabetes, sometimes only after other drugs.
- Ask your pharmacist to run a test claim; it shows whether your plan pays before you fill.
- Use Ontario's coverage checker again later, since listings change.
- “Research” tirzepatide sold online is unauthorized; Health Canada seized such products in 2025.
What tirzepatide users report
- 93 published anonymous tirzepatide confessions; 27 mention at least one side effect.
- 10 mention Mounjaro or Zepbound by name.
- Among confessions that state a weight change in pounds, the median reported is 50 lb. Self-reported, unverified.
Most-mentioned side effects (share of tirzepatide confessions):
- Heart rate or palpitations: 11.8% (11)
- Anxiety or panic: 5.4% (5)
- Burping: 4.3% (4)
- Insomnia or poor sleep: 3.2% (3)
- Libido: 3.2% (3)
Counts are phrase mentions in anonymous accounts, not diagnoses or clinical rates. Full breakdown and methodology: tirzepatide side-effects report.
By province and city
Related
Frequently asked questions
- Is Mounjaro covered by OHIP?
- No. OHIP doesn't cover take-home prescriptions. Ontario's public drug coverage is the Ontario Drug Benefit (ODB), and the ODB formulary listed no tirzepatide (Mounjaro or Zepbound) product when we checked on October 15, 2026.
- Will Ontario cover Mounjaro for type 2 diabetes?
- It might. In August 2026 Canada's Drug Agency recommended public plans cover Mounjaro for type 2 diabetes using the same criteria they use for other GLP-1s such as Ozempic, if the price is reduced. Each province still decides, usually after national price negotiations.
- Is Mounjaro covered by OHIP+?
- No. OHIP+ (for people 24 and under without a private plan) uses the ODB formulary, which does not list Mounjaro.
- What is covered instead in Ontario?
- For type 2 diabetes, Ozempic and generic semaglutide injections are Limited Use ODB benefits when metformin is inadequate or unsuitable. No GLP-1 is covered by ODB for weight loss.
- Does this page recommend a clinic, product or dose?
- No. We don't list clinics, sellers, prices or doses, and nothing here is medical advice. Talk to a licensed Ontario prescriber or pharmacist.
Sources
- Ontario Drug Benefit Formulary search (formulary.health.gov.on.ca)
- Check medication coverage, Ontario Drug Benefit (ontario.ca)
- Canada's Drug Agency recommendation: tirzepatide (Mounjaro), August 2026 (Canadian Journal of Health Technologies)
- Canada's Drug Agency recommendation: tirzepatide (Zepbound), August 2026 (Canadian Journal of Health Technologies)
- Drug Product Database (health-products.canada.ca)
General information only — not medical, legal or regulatory advice. Peptide Confessions does not sell, source or recommend any product or vendor, and nothing here is dosing guidance. Speak with a licensed Canadian healthcare professional or pharmacist about any medication. Editorial process →